© 2000 by European Society of Cardiology
Copyright © 2000, European Society of Cardiology
Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm
Department of Medicine and Aging, University of Chieti "G D’Annunzio" School of Medicine, Chieti, Italy
* Corresponding author. Centro per la Prevenzione dell’Aterosclerosi, la Diagnosi e Terapia dell’Ipertensione Arteriosa e delle Dislipidemie, Nuovo Policlinico SS. Annunziata, Via dei Vestini 66, 66013 Chieti, Italy. Tel.: +39-0871-3556-462; fax: +39-0871-3556-462 mezzetti{at}unich.it
Long-term vascular complications still represent the main cause of morbidity and mortality in diabetic patients. Although randomized long-term clinical studies comparing the effects of conventional and intensive therapy have demonstrated a clear link between hyperglycemia and the development of complications of diabetes, they have not defined the mechanism through which excess glucose results in tissue damage. Evidence has accumulated indicating that oxidative stress may play a key role in the etiology of diabetic complications. Isoprostanes are emerging as a new class of biologically active products of arachidonic acid metabolism of potential relevance to human vascular disease. Their formation in vivo seems to reflect primarily, if not exclusively, a nonenzymatic process of lipid peroxidation. Enhanced urinary excretion of 8-iso-PGF2
has been described in association with both type 1 and type 2 diabetes mellitus, and correlates with impaired glycemic control. Besides providing a likely noninvasive index of lipid peroxidation in this setting, measurements of specific F2 isoprostanes in urine may provide a sensitive biochemical end point for dose-finding studies of natural and synthetic inhibitors of lipid peroxidation. Although the biological effects of 8-iso-PGF2 in vitro suggest that it and other isoeicosanoids may modulate the functional consequences of lipid peroxidation in diabetes, evidence that this is likely in vivo remains inadequate at this time.
KEYWORDS Cholesterol; Coronary disease; Diabetes; Free radicals; Lipid metabolism
Related Article
CiteULike 
Connotea 
Del.icio.us What's this?
Cardiovasc Res 2003 57: 869.
This article has been cited by other articles:
|
|
 |
|
  J. Y. Kim, Y. J. Hyun, Y. Jang, B. K. Lee, J. S. Chae, S. E. Kim, H. Y. Yeo, T.-S. Jeong, D. W. Jeon, and J. H. Lee Lipoprotein-associated phospholipase A2 activity is associated with coronary artery disease and markers of oxidative stress: a case-control study Am. J. Clinical Nutrition, September 1, 2008; 88(3): 630 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Nitenberg Macrovascular disease in type 2 diabetes: We do need animal models for in vivo studies Cardiovasc Res, February 1, 2007; 73(3): 450 - 452. [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ishikawa, T. Nishikimi, K. Akimoto, K. Ishimura, H. Ono, and H. Matsuoka Long-Term Administration of Rho-Kinase Inhibitor Ameliorates Renal Damage in Malignant Hypertensive Rats Hypertension, June 1, 2006; 47(6): 1075 - 1083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Wolfram, A. Oguogho, B. Palumbo, and H. Sinzinger Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF2{alpha} Eur J Heart Fail, March 2, 2005; 7(2): 167 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pagnin, G. Fadini, R. de Toni, A. Tiengo, L. Calo, and A. Avogaro Diabetes Induces p66shc Gene Expression in Human Peripheral Blood Mononuclear Cells: Relationship to Oxidative Stress J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 1130 - 1136. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Srivastava, M. Spite, J. O. Trent, M. B. West, Y. Ahmed, and A. Bhatnagar Aldose Reductase-catalyzed Reduction of Aldehyde Phospholipids J. Biol. Chem., December 17, 2004; 279(51): 53395 - 53406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hansel, P. Giral, E. Nobecourt, S. Chantepie, E. Bruckert, M. J. Chapman, and A. Kontush Metabolic Syndrome Is Associated with Elevated Oxidative Stress and Dysfunctional Dense High-Density Lipoprotein Particles Displaying Impaired Antioxidative Activity J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4963 - 4971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F Violi, L Loffredo, L Musella, and A Marcoccia Should antioxidant status be considered in interventional trials with antioxidants? Heart, June 1, 2004; 90(6): 598 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Bagi, A. Koller, and G. Kaley PPAR{gamma} activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes Am J Physiol Heart Circ Physiol, February 1, 2004; 286(2): H742 - H748. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. POLIAKOV, M.-L. BRENNAN, J. MACPHERSON, R. ZHANG, W. SHA, L. NARINE, R. G. SALOMON, and S. L. HAZEN Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo FASEB J, December 1, 2003; 17(15): 2209 - 2220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Bagi, A. Koller, and G. Kaley Superoxide-NO interaction decreases flow- and agonist-induced dilations of coronary arterioles in Type 2 diabetes mellitus Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1404 - H1410. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kuroki, K. Isshiki, and G. L. King Oxidative Stress: The Lead or Supporting Actor in the Pathogenesis of Diabetic Complications J. Am. Soc. Nephrol., August 1, 2003; 14(90003): S216 - 220. [Full Text] [PDF]
|
|
|
|
|
|
F Cipollone, M Fazia, A Iezzi, B Pini, F Costantini, D De Cesare, L Paloscia, G Materazzo, E D'Annunzio, T Bucciarelli, et al. High preprocedural non-HDL cholesterol is associated with enhanced oxidative stress and monocyte activation after coronary angioplasty: possible implications in restenosis Heart, July 1, 2003; 89(7): 773 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Madore, N. Harvey, J. Parent, P. Chapdelaine, J. A. Arosh, and M. A. Fortier An Aldose Reductase with 20alpha -Hydroxysteroid Dehydrogenase Activity Is Most Likely the Enzyme Responsible for the Production of Prostaglandin F2alpha in the Bovine Endometrium J. Biol. Chem., March 21, 2003; 278(13): 11205 - 11212. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Chiarelli, F. Cipollone, A. Mohn, M. Marini, A. Iezzi, M. Fazia, S. Tumini, D. De Cesare, M. Pomilio, S. D. Pierdomenico, et al. Circulating Monocyte Chemoattractant Protein-1 and Early Development of Nephropathy in Type 1 Diabetes Diabetes Care, October 1, 2002; 25(10): 1829 - 1834. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Block, M. Dietrich, E. P. Norkus, J. D. Morrow, M. Hudes, B. Caan, and L. Packer Factors Associated with Oxidative Stress in Human Populations Am. J. Epidemiol., August 1, 2002; 156(3): 274 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Eckel, M. Wassef, A. Chait, B. Sobel, E. Barrett, G. King, M. Lopes-Virella, J. Reusch, N. Ruderman, G. Steiner, et al. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: Pathogenesis of Atherosclerosis in Diabetes Circulation, May 7, 2002; 105 (18): e138 - e143. [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dietrich, G. Block, M. Hudes, J. D. Morrow, E. P. Norkus, M. G. Traber, C. E. Cross, and L. Packer Antioxidant Supplementation Decreases Lipid Peroxidation Biomarker F2-isoprostanes in Plasma of Smokers Cancer Epidemiol. Biomarkers Prev., January 1, 2002; 11(1): 7 - 13. [Abstract] [Full Text]
|
|
|
|
|
|
M. Y Abeywardena and R. J Head Longchain n-3 polyunsaturated fatty acids and blood vessel function Cardiovasc Res, December 1, 2001; 52(3): 361 - 371. [Abstract] [Full Text] [PDF]
|
|